Hypoxia up-regulates SERPINB3 through HIF-2&#945; in human liver cancer cells. by Cannito, S et al.
Oncotarget1www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Advance Publications 2014
Hypoxia up-regulates SERPINB3 through HIF-2α in human liver 
cancer cells
Stefania Cannito1,*, Cristian Turato2,*, Claudia Paternostro1, Alessandra Biasiolo2, 
Sebastiano Colombatto3, Irene Cambieri4, Santina Quarta2, Erica Novo1, Elisabetta 
Morello1, Gianmarco Villano2, Silvano Fasolato2, Tiziana Musso5, Ezio David6, 
Ignazia Tusa7, Elisabetta Rovida7, Riccardo Autelli1, Antonina Smedile8, Umberto 
Cillo9, Patrizia Pontisso2 and Maurizio Parola1
1 Department of Clinical and Biological Sciences, Unit of Experimental Medicine and Interuniversity Center for Liver 
Pathophysiology, University of Torino, Italy
2 Department of Medicine, University of Padova, Italy
3 Department of Oncology, University of Torino, Italy
4 Department of Plastic Surgery and Burn Unit Skin Bank, CTO Hospital, Torino, Italy
5 Department of Public Health and Pediatric Sciences, University of Torino, Italy 
6 Pathology Unit, San Giovanni Battista Hospital, Torino, Italy
7 Department of Biomedical, Experimental and Clinical Sciences “Mario Serio”, University of Firenze, Italy 
8 Gastroenterology and Hepatology Division, San Giovanni Battista Hospital, Torino, Italy
9 Unit of Hepatobiliary Surgery and Liver Transplantation, University of Padova, Italy 
* These authors contributed equally to this work
Correspondence to: Maurizio Parola, email: maurizio.parola@unito.it
Keywords: SERPINB3, hypoxia, hepatocellular carcinoma, HIF-2α, reactive oxygen species 
Received: September 01, 2014 Accepted: December 09, 2014 Published: December 10, 2014
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original author and source are credited. 
ABSTRACT
SERPINB3 is a cysteine-proteases inhibitor up-regulated in a significant number 
of cirrhotic patients carrying hepatocellular carcinoma (HCC) and recently proposed 
as a prognostic marker for HCC early recurrence. SERPINB3 has been reported to 
stimulate proliferation, inhibit apoptosis and, similar to what reported for hypoxia, to 
trigger epithelial-to-mesenchymal transition (EMT) and increased invasiveness in liver 
cancer cells. This study has investigated whether SERPINB3 expression is regulated 
by hypoxia-related mechanisms in liver cancer cells. 
Exposure of HepG2 and Huh7 cells to hypoxia up-regulated SERPINB3 
transcription, protein synthesis and release in the extracellular medium. Hypoxia-
dependent SERPINB3 up-regulation was selective (no change detected for SERPINB4) 
and operated through hypoxia inducible factor (HIF)-2α (not HIF-1α) binding to 
SERPINB3 promoter, as confirmed by chromatin immuno-precipitation assay and 
silencing experiments employing specific siRNAs. HIF-2α-mediated SERPINB3 up-
regulation under hypoxic conditions required intracellular generation of ROS. Immuno-
histochemistry (IHC) and transcript analysis, performed in human HCC specimens, 
revealed co-localization of the two proteins in liver cancer cells and the existence of 
a positive correlation between HIF-2α and SERPINB3 transcript levels, respectively. 
Hypoxia, through HIF-2α-dependent and redox-sensitive mechanisms, up-
regulates the transcription, synthesis and release of SERPINB3, a molecule with a 
high oncogenic potential.
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INTRODUCTION 
Hypoxic areas, heterogeneously distributed within 
the neoplastic mass, represent a major and common feature 
of clinically relevant solid malignant tumors, including 
hepatocellular carcinoma (HCC) [1]. Hypoxia may 
develop as a consequence of poor/altered vascularization 
(perfusion-limited O2 delivery), deterioration of diffusion 
geometry (diffusion-limited O2 delivery) or to conditions 
of tumor- or therapy-associated anemia [1]. Although 
low oxygen tension may even contribute to kill some 
tumor cells, hypoxia is currently believed to provide a 
strong selective pressure able to regulate tumor growth 
and eventually favor proliferation and survival of the 
most aggressive malignant cells [1-6]. Along these lines, 
the detection of hypoxic areas within a neoplastic mass 
is considered as an independent prognostic indicator 
of poor outcome with a significant risk to develop 
metastasis that may escape therapy [1,3,6-8]. Indeed, 
neoplastic cells surviving hypoxia exhibit enhanced 
invasive propensity, suggesting that hypoxia may favor 
cancer progression [1-8]. Accordingly, hypoxia triggers 
epithelial-to-mesenchymal transition (EMT) in human 
cancer cells (including hepatic cancer cells) [9-11]. EMT 
is a differentiation and/or morphogenetic process involved 
in embryogenesis that has been proposed to contribute 
also to an increased invasiveness of cancer cells, cancer 
progression and metastasis [11-13]. 
Epidemiological analysis indicate that HCC, which 
develops usually in a cirrhotic background whatever the 
etiology (main risk factors being hepatitis B and C viral 
infections, alcohol abuse and metabolic syndrome), is 
at present one of the leading cause of cancer-related 
mortality worldwide. HCC has an extremely negative 
prognosis due to the fact that the majority of patients are 
diagnosed at an advanced stage, as well as to the lack of 
effective treatment, the high risk for tumor recurrence 
and the substantial lack of reliable markers predictive 
of recurrence [14,15]. In the last decade several studies 
have increased our knowledge on either the significance 
of molecular mechanisms of hepatic carcinogenesis, 
signal transduction pathways linked to HCC biology, then 
outlining potential therapeutic targets as well as molecular 
changes that may be useful as diagnostic or prognostic 
markers [16,17]. 
Along these lines, SERPINB3 a member of the 
ovalbumin-serine proteases inhibitor family (ov-serpins) 
[18], has been detected in several malignancies of 
epithelial origin, including HCC [19-23]. Concerning 
HCC, SERPINB3 and its isoform SERPINB4 (formerly 
known as squamous cell carcinoma antigen-1 or SCCA-
1 and squamous cell carcinoma antigen-2 or SCCA-2, 
respectively), are undetectable in normal hepatocytes. 
However, their expression increases progressively in 
chronic liver diseases, in HCC cells and in cells of highly 
dysplastic nodules and hepatocytes of peri-tumoural 
cirrhotic tissue, suggesting that they may represent a 
relatively early event in hepatocarcinogenesis [21,24-26]. 
Indeed, although its precise in vivo role has not been 
identified yet, SERPINB3 has been reported in vitro to 
protect tumor cells from induction of apoptosis [27] and 
to induce epithelial-mesenchymal transition (EMT) and 
increased invasiveness as well as cell proliferation [28]. 
Moreover, SERPINB3/4 have been recently shown to be 
up-regulated by oncogenic Ras and to be able to promote 
NF-kB-related inflammatory cytokine production favoring 
tumor progression [23].
SERPINB3 has also been detected in the majority 
of hepatoblastomas, where the highest levels were found 
in tumors of more advanced stage [29]. Of interest, a very 
recent study performed in HCC specimens from surgically 
resected patients with adequate clinical follow-up revealed 
that high levels of SERPINB3 were detectable in 22% 
of HCC specimens and were found to be significantly 
associated with early tumor recurrence, then representing 
a subset of most aggressive HCCs [30]. 
However, we still ignore the nature of stimuli able 
to up-regulate SERPINB3 expression in chronic liver 
diseases and, in particular, in HCC. As mentioned earlier, 
in a previous study we reported that SERPINB3 was able 
to trigger EMT and increased invasiveness in HepG2 cells 
and human hepatocytes, possibly acting as a paracrine/
autocrine mediator [28]. EMT induction triggered by 
SERPINB3, in particular, closely resembled the scenario 
observed by us [10] and others [11,31] in cancer cells 
of different origin exposed to hypoxic conditions, with 
hypoxia-induced EMT found to involve hypoxia-inducible 
factors (HIFs), a family of heterodimeric transcription 
factors acting as master regulators of homeostatic 
responses to low oxygen tension [5-8]. Hypoxic areas are 
commonly detected in HCC specimens and a preliminary 
gene data analysis revealed that the consensus core HRE 
(hypoxia-responsive element) RCGTG sequences are 
present at the SERPINB3 promoter (Supplemental Figure 
1) [32]. 
In the present study, performed on human HCC cell 
lines and HCC specimens, we report for the first time that 
SERPINB3 is up-regulated by hypoxic conditions through 
a selective HIF-2α-dependent mechanism in liver cancer 
cells and then released in a paracrine way. In keeping 
with these findings, a positive correlation between HIF-
2α and SERPINB3 was detected at transcript and protein 
level in HCC specimens. In particular, the sub-population 
of patients with higher levels of transcripts for both 
molecules carried the most aggressive form of HCC, with 
early tumor recurrence.
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RESULTS 
SERPINB3 expression in liver cancer cells is up-
regulated by hypoxia
In order to identify a possible link between hypoxia 
and SERPINB3 expression we performed immuno-
histochemistry analyses on serial sections obtained from 
a series of human HCC specimens (n=18) developed in 
cirrhotic livers (HCV etiology, G1 and G2 grading) and 
positive for SERPINB3. This preliminary analysis, showed 
that SERPINB3 (SB3) immuno-positivity was detectable 
in the same cells and areas positive for either HIF-1α and 
VEGF, supporting the hypothesis of a correlation between 
hypoxia and SERPINB3 expression (Supplemental Figure 
2A,B). We therefore started to investigate the link between 
hypoxia and SERPINB3 expression by performing a first 
series of experiments in which two human liver cancer 
cell lines (HepG2 and Huh7 cells) were initially exposed 
to moderate hypoxia (3% O2) for up to 96 hrs. Under 
these experimental conditions HepG2 and Huh7 cells 
showed no significant signs of cell death, either necrotic or 
apoptotic, as already previously reported [10]. Exposure to 
hypoxia (3% O2) resulted in a significant up-regulation of 
SERPINB3 mRNA transcription, as quantified by Q-PCR 
(Figure 1A,B), that was apparently earlier in HepG2 
cells (6 hr) than in Huh7. In HepG2, hypoxia-induced 
SERPINB3 transcription was maximal at 24 hrs and 
declined at later time points (Figure 1A). In preliminary 
experiments exposure of HepG2 to more severe conditions 
of hypoxia (0.1% O2) still resulted in early up-regulation 
of SERPINB3 transcripts (1 and 3 hrs, Supplemental 
Figure 3) but also in subsequent induction of significant 
cell death (data not shown). Whether the synthesis of the 
protein is concerned, as determined by ELISA, exposure 
of both HepG2 and Huh7 cells to hypoxia (3% O2) 
Figure 1: Hypoxic conditions up-regulate SERPINB3 (SB3) expression. Panels A,B. Time-dependent analysis of SERPINB3 
transcripts by quantitative real-time PCR (Q-PCR) in HepG2 (panel A) or Huh7 (panel B) cells not exposed (control, C) or exposed to 
hypoxic conditions (HYP) for the indicated times (*p< 0.05 vs control values of SB3; **p< 0.01 vs control values of SB3) . Panels C,D. 
Time-dependent analysis of SERPINB3 protein levels (ng/ml) by ELISA in cellular extracts (white columns) or culture medium (black 
columns) of HepG2 (panel C) or Huh7 (panel D) cells not exposed (control, C) or exposed to hypoxia (HYP) for the indicated times. Data 
are expressed as means ± SEM of three independent experiments (*p< 0.01 vs control values of SB3 in cellular extracts; #p< 0.01 vs control 
values of SB3 release in culture medium).
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similarly induced (Figure 1C,D): a) a marked increase 
in intracellular SERPINB3 protein levels, that became 
detectable after 24 hrs of incubation, lasted until 72 hrs 
to decline at 96 hrs time point; b) a marked and delayed 
release of SERPINB3 in the extracellular medium that 
became detectable after 72 hrs (HepG2 cells) or 48 hrs 
(Huh7 cells). Up-regulation of SERPINB3 mRNA levels 
and protein synthesis as well as the delayed release of 
SERPINB3 protein in the extracellular medium was also 
detected in HT-29 human colon cancer cells exposed to 
identical conditions of hypoxia (Supplemental Figure 
4A,B), suggesting that hypoxia-dependent up-regulation 
of SERPINB3 may be not limited to hepatic cancer cells. 
On the other hand, further experiments showed that 
hypoxia-induced up-regulation of SERPINB3 is a selective 
response since no significant change in transcript levels 
for SERPINB4 (i.e., a serine-protease inhibitor known to 
share a high degree of homology with SERPINB3 [21,23-
26]) was detected in either HepG2 or HuH7 cells exposed 
to hypoxic conditions (Suppl. Figure 5A,B). 
Hypoxia-induced SERPINB3 up-regulation is 
dependent on HIF-2α
HIF-1α protein, a master regulator of hypoxia-
induced responses, is increased in HepG2 cells exposed to 
hypoxia (Figure 2A) and consensus core HRE (hypoxia-
responsive element) RCGTG sequences are present at 
the SERPINB3 promoter (Supplemental Figure 1) [32]. 
However, effective silencing of HIF-1α (evaluated as 
protein levels, Figure 2B) in HepG2 cells exposed to 
hypoxia by using a specific siRNA [10] did not prevent 
hypoxia-induced increase of SERPINB3 mRNA 
levels after 24 hrs of hypoxia (i.e., the time point with 
SERPINB3 peak transcription), as verified by RT-PCR 
(Figure 2C) and quantified by Q-PCR (Figure 2D). Since 
SERPINB3 promoter has, close to HRE sequences, one 
Figure 2: Hypoxia-dependent SERPINB3 (SB3) up-regulation is unrelated to HIF-1α. Panel A. Western blot (WB) analysis 
of HIF-1α performed on total extracts of HepG2 cells (equal loading monitored by re-blotting membranes for β-actin) that were maintained 
in normoxic conditions (control, C) or exposed to hypoxia (HYP) for the indicated times. Panel B. WB analysis of HIF-1α expression 
in HepG2 cells not transfected, transfected with non-silencing control (NsC) or transfected with HIF-1α siRNA that were maintained in 
normoxic conditions (control, C) or exposed to hypoxia for 24 hrs. Panel C, D. Analysis of SERPINB3 transcripts by RT-PCR (panel C) or 
Q-PCR (panel D) in HepG2 cells treated as in (B) or as indicated.
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CGGA and four GGAC sequences (Supplemental Figure 
1), which are ETS sites proposed to increase HIF-2α (not 
HIF-1α) binding affinity, [33,34] we then analyzed the 
possible involvement of HIF-2α. A time course analysis 
showed that hypoxia induced an early (30-60 min) and 
sustained (up to 24 hrs) increase of HIF-2α in HepG2 cells 
(Figure 3A). Moreover, following efficient silencing of 
HIF-2α with siRNA (Figure 3B), SERPINB3 transcripts, 
as verified by RT-PCR (Figure 3C) and quantified by 
Q-PCR (Figure 3D), as well as intracellular SERPINB3 
protein levels (Figure 3E) were almost completely 
abolished in HepG2 cells exposed to hypoxia (24 hrs) as 
compared with related controls.
In order to confirm the selective cause-effect 
relationships between HIF-2α and SERPINB3 up-
regulation we performed further experiments in HepG2 
cells stably transfected in order to over-express either HIF-
1α (H/1α) or HIF-2α (H/2α) (Figure 4A,B). As evaluated 
by Q-PCR only HepG2 cells genetically manipulated 
to over-express HIF-2α also showed up-regulation 
of SERPINB3 mRNA levels, but not of SERPINB4, 
confirming the selectivity of the relationships. 
Figure 3: Hypoxia-dependent SERPINB3 (SB3) up-regulation involves HIF-2α. Panel A. WB analysis of HIF-2α protein 
levels performed on total extracts of HepG2 cells (equal loading monitored by re-blotting membranes for β-actin) that were maintained 
in normoxic conditions (control, C) or exposed to hypoxia (HYP) for the indicated times. Panel B. WB analysis of HIF-2α expression 
in HepG2 cells not transfected, transfected with non-silencing control (NsC) or transfected with HIF-2α siRNA that were maintained in 
normoxic conditions (control, C) or exposed to hypoxia for 24 hrs. Panels C, D. Analysis of SERPINB3 transcripts by RT-PCR (panel C) 
or Q-PCR (panel D) in HepG2 cells treated as in (B) or as indicated. Panel E. ELISA analysis of intracellular SERPINB3 protein levels 
(ng/ml) in HepG2 cells treated as mentioned in (B-D). Data are expressed as means ± SEM of three independent experiments (* p<0.01 vs 
control values; # p<0.01 vs related treatment condition).
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HIF-2α binds to SERPINB3 promoter
Relationships between hypoxia, HIF-2α and 
SERPINB3, were further investigated on cytosolic and 
nuclear fractions obtained from HepG2 exposed to 
hypoxia (Figure 5A,B). A significant increase in nuclear 
HIF-2α protein levels was already detectable after 1 hr 
and then strongly enhanced after 24 hrs. By performing 
a ChIP assay in HepG2 cells we found that, as verified 
by RT-PCR (Figure 5C) and quantified by Q-PCR (Figure 
5D) in normoxic HepG2 cells HIF-2α was not bound 
to SERPINB3 promoter. In keeping with the absence 
of expression of SERPINB3 in control cells and low 
recruitment of RNA polymerase type II (RNApol II) at 
SERPINB3 promoter in normoxia, this indicates that 
transcription at this site is inactive under normal levels of 
oxygen. Following 3 hrs of exposure to hypoxia, HIF-2α 
and RNApol II bound to SERPINB3 promoter in keeping 
with the expression of SERPINB3 mRNA. Additional 
ChIP assay performed in the same experimental conditions 
excluded the binding of HIF-1α to SERPINB3 promoter 
(Supplemental Figure 6), confirming the possible 
involvement of HIF-2α in hypoxia–induced SERPINB3 
expression. 
Hypoxia-induced SERPINB3 up-regulation 
involves intracellular generation of ROS
We previously showed that ROS of mitochondrial 
origin are produced in a number of cell lines (including 
HepG2 cells) following exposure to hypoxia and that 
these ROS can affect HIF1-α recruitment/stabilization, 
[10] in line with established literature evidence [35]. 
Exposure of HepG2 cells to hypoxia resulted in an early 
(15 minutes, Figure 6A-C) and transient (sustained up 
to 3 hrs, declining afterward) increase in intracellular 
ROS (DCFH-DA technique, hydrogen peroxide or H2O2 
used as positive control). This effect was observed also 
in Huh7 cells (Supplemental Figure 7) and was almost 
completely abolished by pre-treating HepG2 cells with 
either the mitochondrial electron chain inhibitor rotenone 
or the more general inhibitor of flavin-dependent enzymes 
DPI (Figure 6A,B). Rotenone is known to block hypoxia-
related mitochondrial release of ROS whereas DPI can 
also block NADPH-oxidase dependent generation of ROS, 
which has also been suggested to play a role in hypoxic 
conditions. However, the use of the more specific inhibitor 
of NADPH-oxidase activity apocynin (Figure 6B) was 
unable to significantly prevent hypoxia-dependent ROS 
generation in our experimental conditions, suggesting 
that intracellular ROS generated under our conditions 
of hypoxia should be mainly of mitochondrial origin. 
Identical results (i.e., early ROS increase following 
hypoxia, abolished by short pre-treatment with rotenone) 
were obtained in experiments in which intracellular 
ROS generation was measured by DCFH-DA technique 
combined to cytofluorimetric analysis (Figure 6C). 
Intracellular ROS generation was also confirmed by the 
rapid increase of heme oxygenase-1 (HO-1) protein levels, 
a well established early “sensor” of intracellular redox 
changes [36], as shown in vitro in HepG2 cells (Figure 
6D). Accordingly, immuno-histochemistry analysis 
performed in serial sections from human HCC tissue 
positive for SERPINB3 (Figure 6E), showed positive 
staining in the same areas/cells also for HO-1 and HIF-
2α. Moreover, we found that exposure of HepG2 cells to 
H2O2 resulted in an early (1 hour) recruitment/stabilization 
of HIF-2α (Figure 6F), as already described for HIF-1α 
[35]. Accordingly, pre-treatment with either rotenone or 
DPI prevented hypoxia-induced SERPINB3 transcription 
at 6 hrs, as quantified by Q-PCR (Figure 6G), indicating 
the involvement of ROS in this phenomenon. This finding 
is fully in agreement with previously published data 
suggesting that hypoxia- and mitochondria-derived ROS 
act likely by affecting prolyl-hydroxylases [35]. Indeed, 
SERPINB3 mRNA was significantly and rapidly up-
Figure 4: Selective relationships between HIF-2α and 
SERPINB3 up-regulation. A,B. Analysis of SERPINB3, 
SERPINB4 and HIF-1α or HIF-2α transcripts by quantitative 
real-time PCR (Q-PCR) in HepG2 normoxic cells stably 
transfected in order to over-express either HIF-2α (H/2α, panel 
A) or HIF-1α (H/1α, panel B) (*p< 0.01 vs control values of 
transcripts in HepG2 cells transfected with empty vector, H/
pCMV6). 
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regulated in HepG2 normoxic cells following exposure to 
H2O2, suggesting that hypoxia-related transient increase 
in intracellular ROS represents a critical early event 
mediating SERPINB3 up-regulation (Figure 6G). 
SERPINB3 and HIF-2α expression in human 
HCC specimens
In a first series of experiments, designed to 
investigate a possible relationship between HIF-2α 
and SERPINB3 expression directly on HCC tissue, we 
performed immuno-histochemistry (IHC) on paraffin-
included human liver specimens (n=18). These analysis 
offered an overall morphological scenario in which human 
samples were characterized by either i) negativity for 
SERPINB3 and negativity or low/moderately positivity 
for HIF-2α (group 1: 9 patients out of 18, Figure 7A), 
ii) low/moderate SERPINB3 positivity associated with 
more intense staining for HIF-2α (group 2: 5 patients 
out of 18, Figure 7B), iii) intense positive staining for 
both SERPINB3 and for nuclear HIF-2α (group 3: 4 
out of 18 patients, Figure 7C). Along these lines, in a 
recent human study [30] some of us reported that high 
levels of SERPINB3 transcripts were detectable in 15 
out of 67 human HCC specimens (approx. 22%) and that 
high expression levels of SERPINB3 were significantly 
associated with early tumor recurrence. In order to further 
verify the significance of the correlation between HIF-
2α and SERPINB3 we performed Q-PCR analysis of 
both HIF-2α and SERPINB3 transcripts in human HCC 
specimens obtained from the same cohort of 67 well 
characterized patients recently described [30]. Statistical 
analysis extended to all available specimens revealed the 
Figure 5: Hypoxia induces HIF-2α nuclear translocation and its binding to SERPINB3 promoter. Panels A,B. WB analysis 
of HIF-2α in cytosolic (panel A) or nuclear (panel B) fractions obtained from HepG2 cells maintained in normoxic conditions (control, C) 
or exposed for 1 hr or 24 hrs to hypoxia (HYP); equal loading evaluated by re-blotting membranes for α-tubulin or lamin A for cytosol and 
nuclear fractions, respectively. Panels C,D. HepG2 cells were incubated for 3 hrs in normoxia or hypoxia and lysed. Lysates were subjected 
to ChIP using antibodies against HIF-2α, RNApol II or control IgG (rabbit, r; mouse, m). Panel C. RT-PCR for SB3 promoter (pSERPINB3) 
was performed with IPed DNA after IP or using input DNA (INPUT). C- (IP) was a negative control in the absence of antibody. Images 
obtained in one experiment out of three which provided similar results. Panel D. Q-PCR for SB3 promoter. Histograms represent the 
relative quantification of DNA recovered from IP with the indicated antibodies. Values were intra-experimentally normalized for input 
DNA and control IgG. Data represent the average ± SD of one experiment out of two performed in triplicate. The statistical significance of 
differences was determined by the Student’s t-test (*** p < 0.001).
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Figure 6: Hypoxia-dependent SERPINB3 (SB3) up-regulation involves intracellular ROS generation. Panels A,B,C. 
Detection of intracellular ROS (DCFH-DA probe) in HepG2 cells not exposed (control, C), exposed to H2O2 50µM or exposed to hypoxia 
(HYP) for the indicated times detected using fluorescence microscope (panel A, DCFH-DA fluorescence; panel B, number of positive cells 
for field, means ± SEM of three different experiments; * and # p < 0,01 vs control values or related treatment condition, respectively) or by 
employing flow cytometric analysis (panel C). In some experiments HepG2 cells were pre-treated with Rotenone (Rot), DPI or Apocynin 
(APO). (Panel D). WB analysis of HO-1 protein levels on total extracts obtained from HepG2 cells maintained in normoxic conditions 
(control, C) or exposed to hypoxia up to 6 hrs (HYP) (equal loading monitored by reblotting membranes for β-actin). Panel E. IHC analysis 
on serial sections obtained from human SERPINB3 positive HCC (grading G2) developed in a cirrhotic patient, showing that expression of 
SB3 and HIF2-α is detectable in the same areas also positive for HO-1. Panel F. WB analysis of HIF-2α recruitment/stabilization in HepG2 
cells treated with H2O2 50µM. Panel G. Q-PCR analysis of SB3 transcripts in HepG2 cells not exposed (control, C), or exposed to H2O2 or 
hypoxia (HYP) up to 24hrs. In some conditions cells were pre-treated with Rot or DPI. 
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existence of a positive correlation (Spearman r coefficient, 
p < 0.01) between HIF-2α and SERPINB3 transcript levels 
(Figure 7D), supporting the notion that also in vivo HIF-
2α may play a relevant role in increasing SERPINB3 
expression. In agreement with these findings, the highest 
levels of HIF-2α transcription were found in the sub-
class of patients with high (> median value) SERPINB3 
expression (Figure 7E) and previously described to carry 
the higher rate of early tumor recurrence [30].
DISCUSSION 
In a previous study we reported that SERPINB3 
was able to induce EMT-related changes and increased 
invasiveness in HepG2 and MDCK cells [28]. Moreover, 
high levels of SERPINB3 expression were detected in 
the sub-class of HCCs with poor prognosis [30]. Here 
we provide evidence for the first time indicating that 
SERPINB3 expression is significantly and mechanistically 
up-regulated by hypoxia through HIF-2α-dependent 
mechanisms in human liver cancer cells. Of relevance, in 
Figure 7: “In vivo” evidence for HIF-2α and SERPINB3 (SB3) correlation in human HCC. Panels A-C. IHC analysis on 
serial sections of human HCC from cirrhotic patients carrying HCC showing different patterns of expression of SERPINB3 and HIF-2α: 
pattern 1, negative for either SERPINB3 or HIF-2α (panel A); pattern 2, weakly positive for SERPINB3 and positive, mainly cytoplasmic, 
staining for HIF-2α (panel B); pattern 3, intense positive stain for both SERPINB3 and HIF-2α, the latter showing mainly nuclear staining 
(panel C). Original magnification as indicated. Panel D. SERPINB3 and HIF-2α mRNA were analysed by Q-PCR in HCC specimens 
obtained from a cohort of 67 patients. Statistical analysis was performed using Spearman correlation. Panel E. SERPINB3 and HIF-2α 
mRNA were analysed by Q-PCR in relation to low expression (SERPINB3 low; N=52) or high expression (SERPINB3 high; N=15) of 
SERPINB3 mRNA. The y axis represents the relative mRNA amounts of the normalised gene. Central bars represent mean and external 
bars represent s.e.m. The analysis was performed with Mann-Whitney test.
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human HCC specimens the expression of SERPINB3 and 
HIF-2α transcripts was significantly correlated, with high 
levels of both transcripts being found in HCC specimens 
from patients that experienced early HCC recurrence. 
As previously established for HIF-1α, [35,37,38] 
our data indicate that HIF-2α-dependent up-regulation 
of SERPINB3 requires generation of ROS (apparently 
of prevalent mitochondrial origin) and redox-mediated 
signaling. This is based on the following evidence: a) the 
rise in intracellular ROS is a very early (i.e., within 15 
minutes) and transient event (declining after 3 hrs) that 
precedes and parallels HIF-2α recruitment/stabilization, 
its binding to SERPINB3 promoter and subsequent 
SERPINB3 mRNA transcription; b) the early rise of 
both ROS and SERPINB3 mRNA levels was abolished 
by pre-treating cells with rotenone, a pharmacological 
inhibitor of mitochondrial electron transport chain known 
to block hypoxia-induced mitochondrial release of ROS 
and HIF-1α and HIF-2α recruitment/stabilization; c) 
treatment of normoxic cells with H2O2, which is known 
to induce recruitment/stabilization of HIF-1α, can also 
induce recruitment/stabilization of HIF-2α and the rise 
of SERPINB3 mRNA. Moreover, images from human 
HCC specimens indicate that positive stain for HO-1, 
a protein which is known to be expressed in a redox-
sensitive way in tissues undergoing generation of ROS 
[36,39], was detected in the same tumor areas positive 
for HIF-2α and SERPINB3. Results obtained in our 
laboratory demonstrate that hypoxia-dependent and ROS-
related up-regulation of SERPINB3 involves activation 
and phosphorylation of Ras/ERK signaling cascade, 
since the pre-treatment of hypoxic HepG2 cells with 
pharmacological inhibitor of MEK (PD 98059) completely 
abolished SERPINB3 expression (Supplemental Figure 
8). These data are consistent with the results reported by 
Catanzaro et al. which mechanistically demonstrated that 
Ras-induced up-regulation of SERPINB3/4 is dependent 
on MAPK pathway and ERK phosphorylation [23]. 
ROS likely act by inhibiting prolyl hydroxylases, 
[35,37,38] thus preventing HIF-α subunits hydroxylation, 
binding to VHL, ubiquitylation and proteasome 
degradation. 
Selective involvement of HIF-2α recruitment/
stabilization in hypoxia-dependent SERPINB3 up-
regulation was unequivocally established by mechanistic 
experiments indicating that both increased transcription 
of SERPINB3 mRNA and SERPINB3 protein release 
in the extracellular medium were abolished following 
silencing of HIF-2α but not of HIF-1α. Moreover, only 
HepG2 genetically manipulated in order to over-express 
HIF-2α showed increased transcription of SERPINB3 
mRNA levels. Data from ChIP assays revealed that HIF-
2α (not HIF-1α) binds to SERPINB3 promoter very early 
(3 hrs) after exposure to hypoxia and that this is paralleled 
by the binding of RNApol II, indicating that transcription 
of SERPINB3 gene (silent under normoxic condition) is 
active following exposure to hypoxia. HIF-2α binding 
to SERPINB3 promoter occurs (on the basis of primers 
designed to perform ChIP assay) at the level of a region 
containing two CGTG HRE consensus sequences as well 
as the GGAC ETS site that are known to increase HIF-2α 
binding activity [33,34]. This fact may well explain why 
HIF-1α does not bind to SERPINB3 promoter following 
exposure to hypoxia. In addition, it should be noted that 
SERPINB3 up-regulation under conditions of hypoxia is a 
selective event since in the same experimental conditions 
no change was detected in the expression of SERPINB4, 
a serine-protease inhibitor sharing a high degree of 
homology with SERPINB3 [21,23-26]. 
This study unequivocally links SERPINB3 up-
regulation to hypoxia through the action of HIF-2α, 
not HIF-1α. This concept is further supported by either 
immuno-histochemistry analysis performed in a series of 
HCC specimens and by the analysis of SERPINB3 and 
HIF-2α transcript levels in HCC specimens obtained 
from a well characterized cohort of 67 HCC patients [30]. 
Indeed, statistical analysis performed on the latter cohort 
revealed the existence of a positive linear correlation 
between SERPINB3 and HIF-2α transcripts in HCC 
specimens from such patients, and the highest levels of 
HIF-2α were found in the subgroup of patients with high 
SERPINB3, previously characterized for early tumor 
recurrence and poor prognosis. These findings suggest 
that HIF-2α expression is likely to play a role in such a 
negative clinical outcome. 
Along these lines, literature indicates that HIFs, 
detected in most solid tumors, can be considered as 
negative prognostic factors predictive for a worst outcome, 
irrespectively of therapeutic treatment [1-8]. HIF-
activated pathways and target genes, including VEGF-A 
and carbonic anhydrase IX, are believed to significantly 
contribute to the survival and progression of cancer cells, 
with therapeutic targeting of HIFs emerging as a rational 
approach to treat solid tumors [3,5,6]. Although HIF-1α 
and HIF-2α share a high degree of sequence identity, the 
ability to hetero-dimerize with ARNT and to bind to HRE 
sequences in order to activate transcription of common 
genes (including VEGF-A, GLUT1 and ADM-1), relevant 
differences have emerged for these two transcription 
factors [6,8,40,41]. HIF-1α is expressed ubiquitously 
whereas HIF-2α expression is restricted to vascular 
endothelial cells, neural crest-derived cells, type II 
pneumocytes, hepatocytes, cardiomyocytes and interstitial 
kidney cells [8,42,43]. Moreover, HIF-2α (not HIF-1α) 
up-regulates transforming growth factor-α and cyclin D1 
genes as well as c-Myc activity and its overexpression in 
human tumors has been described to correlate with a faster 
rate of neoplastic cell growth [8,44,45]. HIF-2α, at least in 
some cancers, has a greater oncogenic capacity than HIF-
1α and its overexpression (and that of HIF-1α) correlates 
with poor patient outcome in colorectal carcinoma, 
melanoma, ovarian cancer and hepatocellular carcinoma, 
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[8,30,44-46] possibly by promoting Myc activity, and 
radio- and chemo-resistance through indirect suppression 
of p53 activity [8,44-46]. In this connection, HIF-2α may 
act through up-regulation of KLF4, Sox2 and Octamer-4, 
to favor de-differentiation and confirmation of stem-cell 
properties of putative cancer stem cells [8,11,31]. 
Finally, the emerging relationships among hypoxia, 
HIF-2α and SERPINB3 become particularly intriguing on 
the basis of the proposed hypothesis of a switch from HIF-
1 to HIF-2 (and then from HIF-1α to HIF-2α) - dependent 
transcription during chronic hypoxia in solid tumors, 
favoring involvement of cancer stem cells and promoting 
inhibition of apoptosis, induction of cell proliferation and 
invasiveness/metastasis [47,48]. Indeed, although a single 
report has proposed a possible tumor-suppressor role for 
HIF-2α in HCC cells, [49] hypoxia and HIFs (HIF-1α and 
HIF-2α) are currently seen as significant determinants 
of the progression of chronic liver diseases and HCC 
development [49]. Remarkably, SERPINB3, which has 
been identified in the present study as a HIF-2α specific 
target, has been reported to be able to inhibit apoptosis 
and to stimulate proliferation (through c-Myc activation) 
as well as EMT and increased invasiveness in cancer cells 
[27-29], features that fit well with the recently proposed 
prognostic relevance of SERPINB3 whose expression has 
been recently reported to be significantly associated with 
early tumour recurrence and worse clinical outcome [30]. 
Along these lines, preliminary experiments (Supplemental 
Figure 9), performed in normoxic cells exposed to 
hypoxia-conditioned medium (CM-HYP) collected at 
96 hrs from HepG2 exposed to hypoxia (i.e., a medium 
containing high levels of hypoxia-induced SERPINB3 
protein), indicated that the use of a specific SERPINB3 
neutralizing antibody resulted in a significant inhibition 
of CM-HYP-induced proliferation (evaluated as PCNA 
expression, Supplemental Figure 9A) as well as to a less 
extent, CM-HYP-induced invasiveness (Matrigel invasion 
assay, 9B). These preliminary “in vitro” data may suggest 
that SERPINB3 up-regulated by hypoxia may have a role 
in sustaining proliferation and invasiveness of hepatic 
cancer cells, both effects already reported in previous 
studies performed using recombinant human SERPINB3 
or cells overexpressing SERPINB3 [28]. Further studies 
properly designed are necessary to fully confirm this 
hypothesis. 
MATERIALS AND METHOD
Materials
Enhanced chemiluminescence (ECL) reagents, 
nitrocellulose membranes (Hybond-C extra), and 
secondary Cy3-conjugated antibodies were from 
Amersham Pharmacia Biotech Inc. (Piscataway, NJ, USA). 
Monoclonal antibody against SERPINB3 (sc-21767), 
LaminA (sc-20680) and PCNA (sc-25280) or polyclonal 
antibody for HIF-1α (sc-53546) were from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA). Polyclonal 
antibody for HIF-2α and HO-1 were from Novus 
Biologicals (Cambridge, UK) and Stressgen (Victoria, 
BC, Canada), respectively. Monoclonal antibodies for 
α-tubulin and β-actin and all other reagents of analytical 
grade were from Sigma Chemical Co (Sigma Aldrich 
Spa, Milan, Italy), Lipofectamine 2000 (Invitrogen-Life 
Technologies), Plasmid DNA purification NucleoBond 
XtraMIDI (Macherey-Nagel, Germany), pCMV6-Entry 
vectors (Origene, Rockville,MD), Boyden’s chambers 
were from Neuro Probe, Inc. (MD, USA).
Cell lines and culture conditions
Cell lines and culture conditions employed in this 
study, including cell culture under controlled conditions 
of hypoxia, are as previously described [10,39]. HepG2 
and Huh7 cells (American Type Culture Collection, 
USA) were maintained in Dulbecco’s modified Eagle’s 
medium supplemented with 10% fetal-bovine serum, 
100 U/ml penicillin, 100 μg/ml streptomycin and 25 μg/
ml amphotericin-B. To evaluate the role of hypoxia, cells 
were seeded in normoxic conditions to obtain the desired 
sub-confluence level (65-70%) and then incubated in 
strictly controlled hypoxic conditions (3% O2) up to 96 
hours, as previously reported [2,3]. Cellular extracts and 
the corresponding medium were tested for SERPINB3 
protein content by ELISA (SCCA-LISA, Xeptagen, 
Marghera, Italy) using recombinant SERPINB3 protein 
for calibration curve (range 0.02-200 ng/ml). In some 
experiments, we also employed HepG2 stably transfected 
with the human SERPINB3 cDNA in order to over-express 
SERPINB3, or with the empty vector alone as control, 
obtained as previously described [1]. 
Generation and selection of HepG2 cells stably 
overexpressing HIF-1α or HIF-2α
The pCMV6-based mammalian expression vectors, 
empty (used as a control) and encoding HIF-1α or HIF-
2α (OriGene, Rockville, MD) were propagated into E. 
coli (JM109 strain) and purified using Plasmid DNA 
purification NucleoBond XtraMIDI (Macherey-Nagel, 
Germany). HepG2 cells were seeded and then transfected 
24 hr later with 10 μg of each vector using Lipofectamine 
2000 (Invitrogen, Carlsbad, CA). Transfected cells were 
subsequently cultured in normal medium supplemented 
with 400 µg/ml G418 to specifically get rid of non-
transfected cells until the growth rate of transfectants 
paralleled that of non-transfected controls. HIF-1α and 
HIF-2α expression of the generated stable transfectants 
was carefully characterized, after which the cell lines 
Oncotarget12www.impactjournals.com/oncotarget
carrying the empty vector (H/pCMV6) and overexpressing 
either HIF-1α (H/1α) or HIF-2α (H/2α) were then used for 
the experiments described. 
Quantitative real-time PCR (Q-PCR)
RNA extraction, complementary DNA synthesis, 
quantitative real-time PCR (Q-PCR) reactions were 
performed as previously described [30]. SERPINB3 
and HIF-2α mRNA levels were measured by Q-PCR, 
using the SYBR® green method as described [30]. 
The amplification mix was prepared using Roche 
LightCycler FastStart DNA MasterPLUS SYBR Green 
I kit following manufacturer’s instructions and real-
time PCR was performed using LightCycler instrument. 
Oligonucleotide sequence of primers used for RT-PCR 
were: sense, 5’-GCAAATGCTCCAGAAGAAAG-3’, 
reverse 5’-CGAGGCAAAATGAAAAGATG-3’ 
(for human SERPINB3); sense, 
5’-GGAGCCACGGTCTCTCAGTA-3’, reverse 
5’-TGCATCTATGGGGATGAGAA-3’ (for human 
SERPINB4); sense, 5’-CGCTAGACTCCGAGAACAT-3’, 
reverse 5’-GGCTTGAACAGGGATTCAGT-3’ 
(for human HIF2α). Gliceraldehyde-3-phosphate 
dehydrogenase (GAPDH) was used as internal reference 
and co-amplified with target samples using identical 
Q-PCR conditions. In particular, expression of SERPINB3 
and HIF-2α mRNA was also assessed by Q-PCR in 67 
frozen liver tumor samples displaying different patterns 
of SERPINB3 expression (SERPINB3 negative/low 
expression or SERPINB3 high expression) [30]. Samples 
were run in triplicate and mRNA expression was generated 
for each sample. Specificity of the amplified PCR products 
was determined by melting curve analysis and confirmed 
by agarose gel electrophoresis.
Chromatin immuno-precipitation (ChIP)
ChiP and ChIP-PCR were performed as described 
with few modifications [50]. Adherent HepG2 cells were 
treated with 1% formaldehyde for 10 min at 37 °C and 
cross-linking stopped by adding glycine at 0.125 M final 
concentration. Cells were washed twice using ice-cold 
PBS containing protease inhibitors: 1 mM phenyl-methyl-
sulphonyl-fluoride (PMSF), 1 µg/ml aprotinin and 1 µg/
ml pepstatin-A. Cells were harvested with 200 µl (every 
106 cells) of lysis buffer (50 mM Tris–HCl, pH 8.1, 10 
mM EDTA, 1% SDS, 1 mM PMSF, 1 µg/ml aprotinin and 
1 µg/ml pepstatin-A) and lysis performed by incubation 
for 10 min on ice. Cell lysates were then sonicated (80 
pulses, 15 sec on and 28 sec off each, at maximum power 
in a Sonoplus apparatus; Bandelin GM3200) to generate 
DNA fragments of 100-500 bp. After centrifugation 
(13000 rpm, 10 min, 4 °C), the supernatant was 10-fold 
diluted with ChIP dilution buffer (16.7 mM Tris–HCl, pH 
8.1, 167 mM NaCl, 1.2 mM EDTA, 0.01% SDS, 1.1% 
Triton X-100) and 4 % of this sample recovered and 
used as an indicator of chromatin content in each sample 
(input). In a new tube 2 µg antibody was incubated with 
14 µl Protein G-Dynabeads (#100.03D; Life Technologies 
Italia, Monza, Italy ) and 200 µl PBS/Tween-20 0.02%, 
for 1 hour at RT under constant agitation. The bead-
antibody complexes were recovered with a Dyna magnet 
(Life Technologies Italia, Monza, Italy), resuspended in 
100 µl PBS/BSA 100 mg/ml and added to each sample 
to be incubated for 16-18 hours at 4 °C under constant 
agitation. In parallel, each sample was subjected to the 
same procedure without antibody (negative control). 
Antibody-protein-DNA complexes were transferred on 
the magnet and supernatant was removed. After extensive 
washing, complexes were eluted from beads with 500 
µl elution buffer (0.1 M NaHCO3, 1% SDS). Following 
addition of 0.2 M NaCl, all samples, including input, were 
incubated for 4 h at 65 °C to revert cross-linking. After 
treatment with 10 µM RNAase and digestion with 40 
µM proteinase-K, DNA was extracted using QIAcquick 
PCR purification, according to the manufacturer’s 
recommendations (Qiagen, #28106) and DNA eluted 
in 40 µl of elution buffer. ChIP-grade antibodies used 
were: rabbit anti-HIF-2α (Novus Biologicals, NB100-
122); mouse anti-RNApol II (Abcam, #ab5408). Other 
antibodies used were: rabbit IgG (Sigma-Aldrich, 
#G5518) and mouse IgG (#M7023) from Sigma-Aldrich. 
Immunoprecipitated DNA was quantified by Quantitative 
Real-Time PCR (Q-PCR). Q-PCR (2 min at 50°C, 5 
min at 95 °C, 45 cycles at 95 °C for 15 sec and 60 °C 
for 1 min) was performed with 2 µl of eluted DNA 
using the ABI Prism 7500 Sequence Detection System 
(Applied Biosystems; Carlsbad, CA, U.S.A.) and Power 
SYBR® Green PCR master mix (Applied Biosystems). 
A melting curve analysis was performed to discriminate 
between specific and non-specific PCR products. The 
relative amount of immunoprecipitated SERPINB3 
promoter DNA was determined using the following 
primers: for 5’-GGAATGATGTACTGATCCATGC-3’’; 
rev 5’-TACTCGAGACCCTGGAAACC-3’. Data were 
normalized by input DNA and expressed with respect to 
those of control IgG (used as calibrator). The amount of 
immunoprecipitated SERPINB3 promoter DNA was also 
monitored by RT-PCR using the same primers indicated 
for Q-PCR.
HIF-1α and HIF-2α silencing by small RNA 
interference
RNA interference experiments to knockdown HIF-
1α or HIF-2α expression in HepG2 cells were performed 
using siRNA duplex (Qiagen Italia, Milano, Italy) as 
previously described [10]. The following target sequences 
were used: 
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HIF-1α: 5’-AGGAAGAACTATGAACATAAA-3’; 
HIF-2α: 5’-CCCGGATAGACTTATTGCCAA-3’.
The siRNAs and related non-silencing controls 
were transfected in HepG2 cells with lipofectamine 2000 
transfection reagent (Life Technologies Italia, Monza, 
Italy) according to manufacturer’s instructions up to 72 
hrs. Transfected cells in fresh medium were then exposed 
for further 48 hrs to the desired experimental conditions 
and then harvested for sample preparation. 
Western Blot analysis
Total cell lysates or nuclear vs cytosolic extracts, 
obtained as described, [10,39] were subjected to sodium 
dodecyl sulfate-polyacrylamide gel-electrophoresis on 
12%, 10% or 7.5% acrylamide gels, incubated with desired 
primary antibodies, then with peroxidase-conjugated anti-
mouse or anti-rabbit immunoglobulins in Tris-buffered 
saline-Tween containing 2% (w/v) non-fat dry milk and 
finally developed with the ECL reagents according to 
manufacturer’s instructions. Sample loading was evaluated 
by reblotting the same membrane with β-actin antibody.
Patients and samples
In the present study we employed HCC specimens 
obtained under written informed consent at the time of 
surgery in 67 patients with cirrhosis of different etiology. 
Clinico-pathological and molecular characteristics of 
these specimens as well as follow-up procedures applied 
to these patients were extensively described in a previous 
study [30]. All the patients underwent surgical resection 
as first-line therapy without pre-operative anticancer 
treatment and distant metastases. Tumour tissue samples 
were collected and part was formalin fixed and paraffin 
embedded, whereas the remaining part was immediately 
frozen at -80 °C for transcript analysis. A series of 18 
paraffin-included liver specimens from cirrhotic HCV 
patients (METAVIR F4) carrying HCC (G1 and G2, 
Edmonson-Steiner grading) was also included in the study 
for immuno-histochemistry analysis.
The use of human material conforms to the ethical 
guidelines of the 1975 Declaration of Helsinki and was 
approved for this study by the Bioethical Committees of 
University of Torino and of Padova.
Immuno-histochemistry
Immuno-histochemistry (IHC) was performed 
on paraffin liver sections of HCC specimens derived 
from patients with hepatitis C virus (HCV)-related liver 
cirrhosis (METAVIR F4). The use of human material 
conforms to the ethical guidelines of the 1975 Declaration 
of Helsinki and was approved for this study by the 
University of Torino Bio-ethical Committee. Immuno-
staining procedure was briefly described: paraffin sections 
(2 μm thick), mounted on poly-L-lysine coated slides, 
were incubated with polyclonal antibody raised against the 
C-terminus of human HIF-2α protein (Novus Biologicals 
Inc.; dilution 1:100) or against heme oxygenase 1 (HO-
1, Stressgen, Vancouver, BC, Canada; dilution 1:100), 
as previously described [7], or the monoclonal antibody 
against SERPINB3 (Santa Cruz Biotechnology, CA, USA; 
dilution 1:50). After blocking endogenous peroxidase 
activity with 3% hydrogen peroxide and performing 
microwave antigen retrieval, primary antibodies were 
labeled by using EnVision, HRP-labeled System (DAKO) 
and visualized by 3’-diaminobenzidine substrate. For 
negative controls the primary antibodies were replaced by 
isotype- and concentrations-matched irrelevant antibody.
Detection of intracellular generation of ROS
Cultured cells, seeded in 12-well culture plates (105 
cells/well), were either exposed to hypoxia or treated or 
not with 50 μM H2O2 under normoxic conditions for 15 
min. ROS generation was detected as the conversion of 
2’,7’-dichlorodihydrofluorescein diacetate (DCFH-DA, 
5 μM) into the corresponding fluorescent derivative. 
Cells were observed and photographed under a Zeiss 
fluorescence microscope [2,6,7]. ROS generation was 
also detected by combining DCFH-DA technique and 
flow cytometric analysis. Cells were seeded in P35 dishes 
(5x105 cells/dish), cultured for 24 hrs and exposed to 
hypoxia alone or hypoxia plus 2.5 μM rotenone for 15 
min before addition of 5 µM DCFH-DA. Cells were 
rapidly washed with PBS, collected by trypsinization 
and re-suspended in PBS for analysis. Detection of DCF 
green fluorescence (FL1) was performed on at least 5,000 
cells per sample with a FACScan equipped with a 488 
nm argon laser using the CellQuest software (Becton-
Dickinson, Milano, Italy). The peak of FL1 intensity of 
DCFH-DA-stained control cells grown under normoxic 
conditions was set to channel 101 and retained for all 
measurements. As a positive control, cells grown under 
normoxic conditions were treated with 50 μM H2O2 for 15 
min, stained with DCFH-DA as above and assayed during 
the same analytical session.
Invasion assay
Invasion assay was performed as previously detailed 
[10] by employing Boyden chambers equipped with 8-µm 
porosity polyvinylpyrrolidone-free polycarbonate filters 
coated with 50 µg/ml of Matrigel solution for invasion 
assay. Invasiveness was quantified by counting, with a 
Zeiss microscope (Oberkochen, Germany) equipped with 
bright-field optics (x40), crystal violet stained cells that 
invaded Matrigel. For each condition, cells were counted 
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in ten randomly chosen fields, averaged as means ± SEM 
and expressed as number of invading cells per high-power 
field. 
Statistical analysis
For cell culture experiments data in bar graphs 
represent means ± SEM, and were obtained from 
average data of at least three independent experiments. 
Luminograms and morphological images are 
representative of at least three experiments with similar 
results. Statistical analysis for these experiments was 
performed by Student’s t-test or ANOVA for analysis 
of variance when appropriate (p < 0.05 was considered 
significant). Statistical analysis designed to assess the 
association of SERPINB3 with HIF-2α expression in liver 
tumors of surgically resected patients were performed by 
non-parametric procedures using the Mann Whitney test. 
Moreover, in order to evaluate simple linear relationships 
between quantitative variables, Spearman’s correlation 
coefficient was applied. All tests were two-sided. The 
calculations were carried out with GraphPad InStat 
Software (San Diego, CA). The null hypothesis was 
rejected at p < 0.05.
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